2
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Conditions
Breast Neoplasms
118
Neoplasms
110
Lung Neoplasms
65
Colorectal Neoplasms
52
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
46
Pancreatic Neoplasms
34
Melanoma
33
Ovarian Neoplasms
29
Neoplastic Cells, Circulating
29
Head and Neck Neoplasms
27
Uterine Cervical Neoplasms
23
Multiple Myeloma
20
Glioma
20
Colonic Neoplasms
20
Carcinoma, Hepatocellular
20
Sarcoma
19
Leukemia, Myeloid, Acute
18
Neoplasm Metastasis
17
Lymphoma
15
Glioblastoma
15
Esophageal Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Hematologic Neoplasms
14
Endometrial Neoplasms
14
Leukemia
13
Myelodysplastic Syndromes
11
Kidney Neoplasms
11
Gastrointestinal Neoplasms
11
Carcinoma, Renal Cell
11
Interventions
eculizumab
3
ublituximab
1
ravulizumab
1
Sugars
1
Rituximab
1
Plasma Exchange
1
OM 89
1
N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide
1
Mitoxantrone
1
LFB-R603
1
Interferon beta-1a
1
Immunoglobulins, Intravenous
1
Blood Specimen Collection
1
Adrenal Cortex Hormones
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelitis, Transverse
×
Blood Specimen Collection
×
Clear all
NCT00704626
2026-05-18
SAA
University of California, Davis
Enrolling by invitation
120 enrolled